Patents Assigned to Biogen Idec
  • Method of treating immunological disorders by administering truncated BAFF receptors
    Patent number: 8303958
    Abstract: The disclosure provides a non-naturally occurring BAFF-R glycoprotein having a deletion in the extracellular domain which results in an altered 0-linked glycosylation pattern. The disclosure also provides methods and pharmaceutical compositions for treating B-cell- and T-cell-mediated disorders.
    Type: Grant
    Filed: August 19, 2011
    Date of Patent: November 6, 2012
    Assignee: Biogen Idec MA Inc.
    Inventors: Christine Ambrose, Jeffrey Thompson, Yen-Ming Hsu, Dingyi Wen, Yaping Sun
  • Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof
    Patent number: 8293237
    Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.
    Type: Grant
    Filed: March 21, 2008
    Date of Patent: October 23, 2012
    Assignees: UCB Pharma, S.A., Biogen Idec MA Inc.
    Inventors: Linda C. Burkly, Janine L. Ferrant-Orgettas, Ellen A. Garber, Yen-Ming Hsu, Lihe Su, Frederick R. Taylor, Ralph Adams, Derek Thomas Brown, Andrew George Popplewell, Martyn Kim Robinson, Anthony Shock, Kerry Louise Tyson
  • Indazole derivatives as modulators of interleukin-1 receptor-associated kinase
    Patent number: 8293923
    Abstract: The present invention relates to modulators of IRAK kinases of formula (I) and provides compositions comprising such modulators, as well as methods therewith for treating IRAK-mediated or IRAK-associated conditions or diseases.
    Type: Grant
    Filed: September 7, 2007
    Date of Patent: October 23, 2012
    Assignee: Biogen Idec MA Inc.
    Inventors: Kevin Guckian, Charles Jewell, Patrick Conlon, Edward Yin Shiang Lin, Timothy Chan
  • Methods of Preventing and Removing Trisulfide Bonds
    Publication number: 20120264916
    Abstract: The present invention pertains to methods of preventing and eliminating trisulfide bonds in proteins such as antibodies. In one embodiment, trisulfide bonds in proteins are converted to disulfide bonds as part of chromatographic purification procedures. In another embodiment, the formation of trisulfide bonds in proteins is inhibited by implementation of methods described herein during the cell culture production of such proteins. In another embodiment, monoclonal antibodies are produced by the methods described herein.
    Type: Application
    Filed: October 1, 2010
    Publication date: October 18, 2012
    Applicant: Biogen Idec MA Inc.
    Inventors: David Evans, R. Blake Pepinsky, Dingyi Wen, Rashmi Rohit Kshirsagar, Karin Lucas
  • ANTI-VLA-4 RELATED ASSAYS
    Publication number: 20120263796
    Abstract: Methods and apparatus for assaying the level of analytes in a sample, related to VLA-4, are disclosed. A method of decreasing the level of an anti-integrin antibody in a subject is described including a) contacting a biological sample from a subject with a detectable capture agent associated with a substrate, wherein the capture agent can bind an anti-integrin antibody in the sample; b) detecting binding of the capture agent with the level of the anti-integrin antibody; and c) treating the subject with plasma exchange until the level of the anti-integrin antibody in the sample reaches a predetermined level.
    Type: Application
    Filed: October 11, 2010
    Publication date: October 18, 2012
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Tatiana Plavina, Paula S. Hochman, Michaela Lerner
  • Soluble lymphotoxin-beta receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological diseases
    Patent number: 8287874
    Abstract: Compositions and methods comprising “lymphotoxin-? receptor blocking agents” which block lymphotoxin-? receptor signalling and are useful for altering immunological diseases, and particularly antibody mediated immune responses.
    Type: Grant
    Filed: June 10, 2010
    Date of Patent: October 16, 2012
    Assignee: Biogen Idec MA Inc.
    Inventors: Jeffrey L. Browning, Paula S. Hochman, Paul D. Rennert, Fabienne Mackay
  • METHODS FOR THE DETECTION OF JC POLYOMA VIRUS
    Publication number: 20120258443
    Abstract: Methods and compositions for determining whether a subject is at risk for PML, including subjects being treated with immunosuppressants, by determining whether the subject harbors a JCV variant with reduced binding for sialic acid relative to a normal JCV, are presented. Furthermore, combinations of JCV-VP1 sequence variations that are associated with PML and that can be used as a basis of an assay for identifying subjects susceptible to PML, subjects with PML (e.g., early stage PML), or subjects at risk of developing PML in response to an immunosuppressive treatment are provided.
    Type: Application
    Filed: February 5, 2010
    Publication date: October 11, 2012
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Leonid Gorelik, Alexey Lugovskoy
  • Treatment for Amyotrophic Lateral Sclerosis
    Publication number: 20120259012
    Abstract: Provided are certain methods of screening, identifying, and evaluating neuroprotective compounds useful for treatment of neurological diseases, such as, e.g., multiple sclerosis (MS). The compounds described upregulate the cellular cytoprotective pathway regulated by Nrf2. Also provided are certain methods of utilizing such compounds in therapy for neurological disease, particularly, for slowing or reducing demyelination, axonal loss, or neuronal and oligodendrocyte death.
    Type: Application
    Filed: May 7, 2012
    Publication date: October 11, 2012
    Applicant: Biogen Idec MA Inc.
    Inventor: Matvey E. LUKASHEV
  • Method for the high level expression of active tumor necrosis receptor family member immunoglobulin fusion proteins
    Patent number: 8283138
    Abstract: Methods for high level expression of active lymphotoxin-? receptor immunoglobulin chimeric proteins and their purification.
    Type: Grant
    Filed: August 17, 2009
    Date of Patent: October 9, 2012
    Assignee: Biogen Idec MA Inc.
    Inventors: Jeffrey L. Browning, Konrad Miatkowski, Werner Meier
  • ANTI-ALPHA V BETA 6 ANTIBODIES
    Publication number: 20120251532
    Abstract: Monoclonal antibodies that specifically bind to M.96. Also included are methods of using these antibodies to treat mammals having or at risk of having 006-mediated diseases, or to diagnose % Qmediated diseases.
    Type: Application
    Filed: April 10, 2012
    Publication date: October 4, 2012
    Applicants: The Regents of the University of California, a California corporation, BIOGEN IDEC MA INC.
    Inventors: Shelia M. Violette, Paul H. Weinreb, Kenneth J. Simon, Dean Sheppard, Diane R. Leone
  • TREATMENT OF DEMYELINATING DISORDERS WITH SOLUBLE LYMPHOTOXIN-BETA-RECEPTOR
    Publication number: 20120244153
    Abstract: The invention relates to the treatment of demyelinating disorders, e.g. multiple sclerosis, using a soluble lymphotoxin beta receptor (LT?R) as an inhibitor of the lymphotoxin pathway.
    Type: Application
    Filed: October 18, 2011
    Publication date: September 27, 2012
    Applicants: UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, BIOGEN IDEC MA INC.
    Inventors: Jeffrey L. BROWNING, Jenny P-Y TING
  • METHOD FOR REDUCING FLU-LIKE SYMPTOMS ASSOCIATED WITH INTRAMUSCULAR ADMINISTRATION OF INTERFERON USING A FAST TITRATION ESCALATING DOSING REGIMEN
    Publication number: 20120237479
    Abstract: The present invention provides a method for treating multiple sclerosis (MS), and for reducing flu-like symptoms associated with administration of an interferon to a patient with MS. The method involves intramuscularly administering the interferon to the MS patient according to an escalating dosing regimen in weeks 1 to 3, and a full therapeutically effective dose of interferon in week 4. In one embodiment of the invention, the escalating dosing regimen comprises administering one quarter of the therapeutically effective dose in week 1, half of the therapeutically effective dose in week 2, and three-quarters of the therapeutically effective dose in week 3. Also provided are titration packages for enabling compliance with a regimen of changing dosage of an interferon over a period of time.
    Type: Application
    Filed: March 15, 2012
    Publication date: September 20, 2012
    Applicant: Biogen Idec Inc.
    Inventor: Aaron DEYKIN
  • Bicyclic aryl sphingosine 1-phosphate analogs
    Patent number: 8269043
    Abstract: Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.
    Type: Grant
    Filed: October 30, 2009
    Date of Patent: September 18, 2012
    Assignee: Biogen Idec MA Inc.
    Inventors: Richard D. Caldwell, Kevin M. Guckian, Gnanasambandam Kumaravel, Wen-Cherng Lee, Edward Yin-Shiang Lin, Xiaogao Liu, Bin Ma, Daniel M. Scott, Zhan Shi, Jermaine Thomas, Arthur G. Taveras, Guo Zhu Zheng
  • NOGO Receptor Binding Protein
    Publication number: 20120230979
    Abstract: The invention provides Sp35 polypeptides and fusion proteins thereof, Sp35 antibodies and antigen-binding fragments thereof and nucleic acids encoding the same. The invention also provides compositions comprising, and methods for making and using, such Sp35 antibodies, antigen-binding fragments thereof, Sp35 polypeptides and fusion proteins thereof.
    Type: Application
    Filed: March 7, 2012
    Publication date: September 13, 2012
    Applicant: Biogen Idec MA Inc.
    Inventors: Sha MI, John McCoy, R. Blake Pepinsky, Daniel H.S. Lee
  • Neublastin variants
    Patent number: 8263553
    Abstract: Compositions and methods for folding proteins belonging to the transforming growth factor beta superfamily are disclosed. The compositions and methods allow for the folding of such proteins when produced in an expression system that does not yield a properly folded, biologically active product.
    Type: Grant
    Filed: August 18, 2005
    Date of Patent: September 11, 2012
    Assignee: Biogen Idec MA Inc.
    Inventors: Anthony Rossomando, Laura Silvian, R. Blake Pepinsky
  • Methods Relating to Peripheral Administration of Nogo Receptor Polypeptides
    Publication number: 20120219567
    Abstract: This invention relates to methods of treating diseases involving accumulation of A? plaques, including Alzheimer's Disease by the peripheral administration of soluble Nogo receptor polypeptides. The invention also provides methods of increasing the plasma to brain ratio of A? peptide and enhancing A? peptide clearance via peripheral administration of soluble Nogo receptor polypeptides. This invention also provides methods of improving memory function or inhibiting memory loss via the peripheral administration of soluble Nogo receptor polypeptides. The invention also provides methods of decreasing the size and number of A? plaques in a mammal via peripheral administration of soluble Nogo receptor polypeptides.
    Type: Application
    Filed: February 21, 2012
    Publication date: August 30, 2012
    Applicants: Biogen Idec MA Inc., Yale University
    Inventors: Stephen M. Strittmatter, Daniel H.S. Lee
  • Cripto Blocking Antibodies and Uses Thereof
    Publication number: 20120195912
    Abstract: The invention provides Cripto blocking antibodies, or biologically functional fragments thereof, and uses thereof. Antibodies which bind Cripto and modulate Cripto signaling are provided. Antibodies which bind Cripto and block the interaction between Cripto and ALK4 are provided. Antibodies which bind Cripto and modulate tumor growth are also provided. Antibodies which bind Cripto, modulate signaling, and modulate tumor growth are also provided. Antibodies which bind Cripto, block the interaction between Cripto and ALK4 and modulate tumor growth are provided. The invention also provides methods of using these antibodies in therapeutic, diagnostic, and research applications.
    Type: Application
    Filed: August 19, 2011
    Publication date: August 2, 2012
    Applicant: Biogen Idec MA Inc.
    Inventors: Michele Sanicola-Nadel, Kevin P. Williams, Susan Gail Schiffer, Paul Rayhorn
  • METHODS AND PRODUCTS FOR EVALUATING AN IMMUNE RESPONSE TO A THERAPEUTIC PROTEIN
    Publication number: 20120195884
    Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab). A second aspect of the invention concerns the chronological details of sample collection for determining the titre of antibodies against the therapeutic protein, e.g. the collection of at least two samples at two different time points. A third aspect of the invention relates to the selection of the critical threshold level, which corresponds to the antibody titre of untreated patients increased by the double of the standard deviation of this control antibody titre.
    Type: Application
    Filed: September 23, 2011
    Publication date: August 2, 2012
    Applicants: Biogen Idec MA Inc., Elan Pharmaceuticals, Inc.
    Inventors: Meena Subramanyam, Lakshmi Amaravadi, Eric Wakshull, Frances Lynn, Michael Panzara, Robin Mcdaid Barbour, Julie Elizabeth Taylor
  • Treatment for Multiple Sclerosis
    Publication number: 20120196931
    Abstract: Provided are certain methods of screening, identifying, and evaluating neuroprotective compounds useful for treatment of neurological diseases, such as, e.g., multiple sclerosis (MS). The compounds described upregulate the cellular cytoprotective pathway regulated by Nrf2. Also provided are certain methods of utilizing such compounds in therapy for neurological disease, particularly, for slowing or reducing demyelination, axonal loss, or neuronal and oligodendrocyte death.
    Type: Application
    Filed: February 13, 2012
    Publication date: August 2, 2012
    Applicant: Biogen Idec MA Inc.
    Inventors: Matvey E. LUKASHEV, Gilmore O'Neill
  • Detection and quantitation of cyclodextrins
    Patent number: 8232064
    Abstract: The invention relates to the detection and quantitation of cyclodextrins and cyclodextrin derivatives in solutions comprising a protein. The invention further relates to methods of evaluating pharmaceutical preparations for the presence of residual cyclodextrins.
    Type: Grant
    Filed: December 5, 2005
    Date of Patent: July 31, 2012
    Assignee: Biogen Idec MA Inc.
    Inventors: Zoran Sosic, Rulin Qian, James Ahern, Rohin Mhatre